MX355261B - Derivado de indanosulfamida novedoso. - Google Patents

Derivado de indanosulfamida novedoso.

Info

Publication number
MX355261B
MX355261B MX2014015492A MX2014015492A MX355261B MX 355261 B MX355261 B MX 355261B MX 2014015492 A MX2014015492 A MX 2014015492A MX 2014015492 A MX2014015492 A MX 2014015492A MX 355261 B MX355261 B MX 355261B
Authority
MX
Mexico
Prior art keywords
sulfamide
inden
dihydro
novel
tetrafluoro
Prior art date
Application number
MX2014015492A
Other languages
English (en)
Other versions
MX2014015492A (es
Inventor
Kazuta Yuji
Watanabe Toru
Sorimachi Keiichi
Saito Minako
Kita Yoichi
Tanaka Toshiaki
Higashiyama Hiroyuki
Hanada Takahisa
Teramoto Tetsuyuki
Kosasa Takashi
Ishikawa Yukio
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of MX2014015492A publication Critical patent/MX2014015492A/es
Publication of MX355261B publication Critical patent/MX355261B/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C307/00Amides of sulfuric acids, i.e. compounds having singly-bound oxygen atoms of sulfate groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C307/04Diamides of sulfuric acids
    • C07C307/08Diamides of sulfuric acids having nitrogen atoms of the sulfamide groups bound to carbon atoms of rings other than six-membered aromatic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/18Sulfonamides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/275Nitriles; Isonitriles
    • A61K31/277Nitriles; Isonitriles having a ring, e.g. verapamil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00Sulfonic acids; Halides, esters, or anhydrides thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00Systems containing two condensed rings
    • C07C2602/02Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Ciertos derivados de indanosulfamida novedosos o una de sus sales farmacéuticamente aceptables, tales como N-[(1S)-2,2,5,7-tetrafluo ro-2,3-dihidro-1H-inden-1-il)sulfamida, N-[(1S)-2,2,4,7-tetrafluor o-2,3-dihidro-1H-inden-1-il]sulfamida, (+)-N-(2,2,4,6,7-pentafluor o-2,3-dihidro-1H-inden-1-il)sulfamida, ejercen la acción de mejorar el índice de intensidad de los ataques (puntaje) en el modelo de actividad propagada en ratones. Por lo tanto, cabe esperar que los compuestos o sus sales actúen como fármacos para tratar la epilepsia.
MX2014015492A 2012-06-21 2013-06-17 Derivado de indanosulfamida novedoso. MX355261B (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261662626P 2012-06-21 2012-06-21
US201261709737P 2012-10-04 2012-10-04
US201361751331P 2013-01-11 2013-01-11
PCT/JP2013/066623 WO2013191144A1 (ja) 2012-06-21 2013-06-17 新規インダンスルファミド誘導体

Publications (2)

Publication Number Publication Date
MX2014015492A MX2014015492A (es) 2015-05-08
MX355261B true MX355261B (es) 2018-04-12

Family

ID=49768740

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014015492A MX355261B (es) 2012-06-21 2013-06-17 Derivado de indanosulfamida novedoso.

Country Status (34)

Country Link
US (1) US9018260B2 (es)
EP (1) EP2865663B1 (es)
JP (1) JP5883135B2 (es)
KR (1) KR101951519B1 (es)
CN (1) CN104395285B (es)
AR (1) AR091506A1 (es)
AU (1) AU2013278450B2 (es)
BR (1) BR112014031565B1 (es)
CA (1) CA2877097C (es)
CL (1) CL2014003429A1 (es)
CY (1) CY1119171T1 (es)
DK (1) DK2865663T3 (es)
ES (1) ES2628374T3 (es)
HK (1) HK1207363A1 (es)
HR (1) HRP20170863T1 (es)
HU (1) HUE033583T2 (es)
IL (1) IL236295A (es)
JO (1) JO3263B1 (es)
LT (1) LT2865663T (es)
ME (1) ME02753B (es)
MX (1) MX355261B (es)
MY (1) MY169073A (es)
NZ (1) NZ702974A (es)
PE (1) PE20150284A1 (es)
PH (1) PH12014502805B1 (es)
PL (1) PL2865663T3 (es)
PT (1) PT2865663T (es)
RS (1) RS56073B1 (es)
RU (1) RU2619937C2 (es)
SG (1) SG11201408359PA (es)
SI (1) SI2865663T1 (es)
TW (1) TWI597263B (es)
WO (1) WO2013191144A1 (es)
ZA (1) ZA201409248B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3043784T (lt) 2013-09-09 2019-08-12 Peloton Therapeutics, Inc. Arilo eteriai ir jų panaudojimo būdai
ES2737148T3 (es) 2013-12-16 2020-01-10 Peloton Therapeutics Inc Análogos de sulfona y sulfoximina cíclicos y usos de los mismos
JP6518595B2 (ja) * 2013-12-19 2019-05-22 エーザイ・アール・アンド・ディー・マネジメント株式会社 1−インダンスルファミド誘導体を含む疼痛の治療および/または予防剤
WO2016144826A1 (en) 2015-03-11 2016-09-15 Peloton Therapeutics, Inc. Substituted pyridines and uses thereof
EP3267792A4 (en) * 2015-03-11 2018-09-26 Peloton Therapeutics, Inc. Compositions for use in treating pulmonary arterial hypertension
US10512626B2 (en) 2015-03-11 2019-12-24 Peloton Therapeautics, Inc. Compositions for use in treating glioblastoma
WO2016144825A1 (en) 2015-03-11 2016-09-15 Peloton Therapeutics, Inc. Aromatic compounds and uses thereof
US10335388B2 (en) 2015-04-17 2019-07-02 Peloton Therapeutics, Inc. Combination therapy of a HIF-2-alpha inhibitor and an immunotherapeutic agent and uses thereof
US9796697B2 (en) 2015-06-12 2017-10-24 Peloton Therapeutics, Inc. Tricyclic inhibitors of HIF-2-alpha and uses thereof
EP3769759B1 (en) * 2018-03-20 2023-11-15 Eisai R&D Management Co., Ltd. Combination of an indanesulfamide derivative with perampanel for use in the treatment of epilepsy
JP2024026905A (ja) * 2020-11-25 2024-02-29 エーザイ・アール・アンド・ディー・マネジメント株式会社 てんかん治療剤
WO2023210617A1 (ja) * 2022-04-27 2023-11-02 エーザイ・アール・アンド・ディー・マネジメント株式会社 パーキンソン病治療用医薬組成物

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3383414A (en) 1964-08-26 1968-05-14 Sandoz Ag Benzocycloalkyl sulfamides
US3709677A (en) 1969-06-25 1973-01-09 Sandoz Ag N-substituted sulfamoyl compounds useful as herbicides
WO2003000654A1 (en) * 2001-06-26 2003-01-03 Yissum Research Development Company Of The Hebrew University Of Jerusalem Valproyltaurinamide derivatives as anticonvulsant and cns active agents
TW200307539A (en) 2002-02-01 2003-12-16 Bristol Myers Squibb Co Cycloalkyl inhibitors of potassium channel function
MY142329A (en) * 2004-08-24 2010-11-15 Janssen Pharmaceutica Nv Novel benzo-fused heteroaryl sulfamide derivatives useful as anticonvulsant agents.
US20070155823A1 (en) * 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives as neuroprotective agents
CN100572365C (zh) * 2006-01-26 2009-12-23 全哲山 用作抗癫痫药的1,2,4-三唑并[4,3-a]喹啉-1-酮衍生物及其可药用盐
JP2009184924A (ja) 2006-05-31 2009-08-20 Eisai R & D Management Co Ltd 生物学的試薬用化合物
CL2007002994A1 (es) 2006-10-19 2008-02-08 Wyeth Corp Compuestos derivados heterociclicos que contienen sulfamoilo, inhibidores de hsp90; composicion farmaceutica; y uso para el tratamiento del cancer, tal como cancer de mama, de colon y prostata, entre otros.
TWI433674B (zh) 2006-12-28 2014-04-11 Infinity Discovery Inc 環杷明(cyclopamine)類似物類
AR070949A1 (es) * 2007-10-19 2010-05-19 Solvay Pharm Gmbh Compuestos derivados de sulfamato de uso medico, medicamentos y composiciones farmaceuticas que los comprenden, procedimientos para preparar estos compuestos y su uso
TW201012803A (en) * 2008-06-06 2010-04-01 Organon Nv Heterocyclic derivatives
JP2012523393A (ja) 2009-04-09 2012-10-04 エム・エス・ディー・オス・ベー・フェー インダン誘導体
EP3868377A1 (en) 2009-11-13 2021-08-25 Receptos Llc Selective sphingosine 1 phosphate receptor modulators and methods of chiral synthesis
DK2498609T3 (en) 2009-11-13 2018-06-18 Celgene Int Ii Sarl SELECTIVE HETEROCYCLIC SPHINGOSIN-1 PHOSPHATRECEPTOR MODULATORS
WO2011097337A1 (en) * 2010-02-04 2011-08-11 Advanced Neural Dynamics, Inc. Novel sulfamides exhibiting neuroprotective action and methods for use thereof
US20120077814A1 (en) * 2010-09-10 2012-03-29 Zhong Wang Sulfonamide, sulfamate, and sulfamothioate derivatives

Also Published As

Publication number Publication date
US9018260B2 (en) 2015-04-28
WO2013191144A1 (ja) 2013-12-27
AU2013278450B2 (en) 2017-04-20
MY169073A (en) 2019-02-13
DK2865663T3 (en) 2017-06-19
BR112014031565A8 (pt) 2021-06-08
TWI597263B (zh) 2017-09-01
KR20150032838A (ko) 2015-03-30
CA2877097A1 (en) 2013-12-27
IL236295A0 (en) 2015-02-26
ME02753B (me) 2018-01-20
PT2865663T (pt) 2017-06-02
BR112014031565A2 (pt) 2017-06-27
JO3263B1 (ar) 2018-09-16
SI2865663T1 (sl) 2017-07-31
PE20150284A1 (es) 2015-02-21
SG11201408359PA (en) 2015-01-29
RU2619937C2 (ru) 2017-05-22
HRP20170863T1 (hr) 2017-09-08
BR112014031565B1 (pt) 2022-04-12
HUE033583T2 (hu) 2017-12-28
EP2865663A4 (en) 2016-02-17
PH12014502805A1 (en) 2015-02-23
CN104395285A (zh) 2015-03-04
AU2013278450A1 (en) 2015-01-22
JP5883135B2 (ja) 2016-03-09
LT2865663T (lt) 2017-07-10
RS56073B1 (sr) 2017-10-31
IL236295A (en) 2016-09-29
CA2877097C (en) 2018-08-07
PL2865663T3 (pl) 2017-09-29
MX2014015492A (es) 2015-05-08
CL2014003429A1 (es) 2015-03-27
RU2014151013A (ru) 2016-08-10
EP2865663B1 (en) 2017-04-05
EP2865663A1 (en) 2015-04-29
PH12014502805B1 (en) 2015-02-23
AR091506A1 (es) 2015-02-11
ES2628374T3 (es) 2017-08-02
TW201402530A (zh) 2014-01-16
JPWO2013191144A1 (ja) 2016-05-26
CN104395285B (zh) 2016-04-13
CY1119171T1 (el) 2018-02-14
ZA201409248B (en) 2015-12-23
KR101951519B1 (ko) 2019-02-22
HK1207363A1 (en) 2016-01-29
US20140371319A1 (en) 2014-12-18
NZ702974A (en) 2016-03-31

Similar Documents

Publication Publication Date Title
PH12014502805A1 (en) Novel indanesulfamide derivative
WO2015031564A3 (en) Substituted-1h-benzo[d]imidazole compounds as lysine-specific demethylase 1 (lsd1 ) inhibitors
WO2014028600A3 (en) 3-AMINOCYCLOALKYL COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
PH12014501967B1 (en) Benzodioxanes in combination with other actives for inhibiting leukotriene production
IN2014DN09434A (es)
AU2012214029A8 (en) Rorgammat inhibitors
MX2016002794A (es) Compuestos antiproliferativos.
MX2013004491A (es) Boronatos como inhibidores de arginasa.
NZ704662A (en) Crystalline forms of the prolyl hydroxylase inhibitor [(4-hydroxy-1-methyl-7-phenoxy-isoquinoline-3-carbonyl)-amino]-acetic acid
IN2014KN00948A (es)
MX2013012542A (es) Compuestos de amida y aplicacion farmaceutica para el mismo.
GEP20156347B (en) Benzodioxane inhibitors of leukotriene production
NZ719169A (en) Heteroaryl butanoic acid derivatives as lta4h inhibitors
WO2014153009A3 (en) Thiosaccharide mucolytic agents
WO2015056094A3 (en) Pharmaceutical composition comprising a trpa1 antagonist and an analgesic agent
MX2021005494A (es) Composicion farmaceutica que comprende un derivado de amida que inhibe el crecimiento de celulas con cancer y lubricante de sal no metalica.
TN2015000107A1 (en) Benzamides
UA117032C2 (uk) Селективний інгібітор фосфатидилінозитол-3-кінази-гамма
TN2013000239A1 (en) New form of administration of enkephalinase inhibitor
MX364220B (es) Metodos de tratamientos de fibrosis.
CA2887539C (en) Azaquinazoline carboxamide derivatives
NZ624726A (en) Methods for treating gout flares
MX370898B (es) Agente terapéutico y/o preventivo que comprende un derivado de 1-indansulfamida para el dolor.
WO2013033602A3 (en) Fatty acid amides, compositions and methods of use
MX362315B (es) Imidazolcarboxamidas y su uso como inhibidores de amida de acidos grasos hidrolasa (faah).

Legal Events

Date Code Title Description
FG Grant or registration